Elanco (NYSE: ELAN) officer reports major equity grants and tax share sale

Rhea-AI Filing Summary

Elanco Animal Health Inc officer Ramiro Martin Cabral reported several equity awards and related share movements. On March 1, 2026, he received an award of 42,570 stock options and separate grants of 60,053 and 20,834 shares of common stock at no cost.

The stock options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, subject to continued service. A separate disposition of 30,150 common shares at $26.40 per share was reported as a tax-withholding transaction, leaving 269,532 common shares held directly afterward.

Insider Trade Summary

Net Buyer: 50,737 shares

Net Buy 4 txns

Insider Cabral Ramiro Martin

Role SEE REMARKS

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	42,570	$0.00	$0.00
Grant/Award	Common Stock	60,053	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	30,150	$26.40	$796K
Grant/Award	Common Stock	20,834	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 42,570 shares (Direct); Common Stock — 290,366 shares (Direct)

Footnotes (2)

1. F1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.
2. F2. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/03/2026 - 07:17 PM Learn about SEC filing dates

FAQ

What insider transactions did Elanco (ELAN) officer Ramiro Martin Cabral report?

He reported equity awards and a tax-related share disposition. On March 1, 2026, he received stock options and common stock grants at no cost, and separately disposed of shares to cover tax obligations tied to these awards.

How many Elanco (ELAN) stock options were granted to Ramiro Martin Cabral?

He was granted 42,570 employee stock options. These options are scheduled to vest in three equal tranches on March 1, 2027, March 1, 2028, and March 1, 2029, contingent on continued service with Elanco Animal Health Inc.

What Elanco (ELAN) common stock awards did Ramiro Martin Cabral receive?

He received two common stock grants of 60,053 and 20,834 shares. Both were reported at a price of $0.00 per share, reflecting equity compensation awards rather than open-market purchases of Elanco’s common stock.

Why did Ramiro Martin Cabral dispose of Elanco (ELAN) shares at $26.40?

He disposed of 30,150 common shares at $26.40 each in a tax-withholding transaction. The filing describes this as using shares to satisfy tax obligations or exercise costs related to his equity compensation awards.

How many Elanco (ELAN) shares does Ramiro Martin Cabral hold after these transactions?

After the reported March 1, 2026 transactions, he directly holds 269,532 shares of Elanco common stock. This figure reflects the net position following the equity grants and the tax-withholding share disposition reported in the Form 4.

When do Ramiro Martin Cabral’s Elanco (ELAN) equity awards vest?

Both the restricted stock units and stock options vest over three years. One-third vests on March 1, 2027, another third on March 1, 2028, and the final portion on March 1, 2029, according to the Form 4 footnotes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cabral Ramiro Martin

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		60,053	A	$0	299,682	D
Common Stock	03/01/2026		F		30,150	D	$26.4	269,532	D
Common Stock	03/01/2026		A		20,834(1)	A	$0	290,366	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$26.4	03/01/2026		A		42,570		(2)	03/01/2036	Common Stock	42,570	$0	42,570	D

Explanation of Responses:

1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

2. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

Remarks:

Executive Vice President - Elanco International

	/s/ Amy C. Seidel, as Attorney-in-Fact for Ramiro Martin Cabral	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.